These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 30528147)
1. [Treatment with oral anticoagulants in older patients: Should warfarin still be prescribed?]. Lafuente-Lafuente C; Oasi C; Belmin J Presse Med; 2019 Feb; 48(2):154-164. PubMed ID: 30528147 [TBL] [Abstract][Full Text] [Related]
2. [Anticoagulation of older patients: what is new?]. Lafuente-Lafuente C; Pautas É; Belmin J Presse Med; 2013 Feb; 42(2):187-96. PubMed ID: 23312927 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
5. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation]. Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H Therapie; 2015; 70(6):485-92. PubMed ID: 26223162 [TBL] [Abstract][Full Text] [Related]
6. Use of oral anticoagulants in complex clinical situations with atrial fibrillation. Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871 [TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
8. Overview of the new oral anticoagulants: opportunities and challenges. Yeh CH; Hogg K; Weitz JI Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448 [TBL] [Abstract][Full Text] [Related]
9. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056 [TBL] [Abstract][Full Text] [Related]
10. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Zirlik A; Bode C J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543 [TBL] [Abstract][Full Text] [Related]
11. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists. Kozlowski D; Budrejko S; Raczak G; Rysz J; Banach M Curr Pharm Des; 2013; 19(21):3816-26. PubMed ID: 23286429 [TBL] [Abstract][Full Text] [Related]
12. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811 [TBL] [Abstract][Full Text] [Related]
13. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Mantha S; Ansell J Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145 [TBL] [Abstract][Full Text] [Related]
14. The new oral anticoagulants: Reasonable alternatives to warfarin. Roca B; Roca M Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894 [TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Ment J Vasc Health Risk Manag; 2015; 11():317-32. PubMed ID: 26089678 [TBL] [Abstract][Full Text] [Related]
16. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Bauer KA Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725 [No Abstract] [Full Text] [Related]